David Bingham is a seasoned Software Engineering Leader with a background in scalable high availability software systems. During more than 30 years in product development, David has contributed to diverse products such as mission-critical communication systems, on-demand video distribution, an enterprise collaboration suite, and highly scalable Customer Experience (CX) Solutions.
Dr. Steven Craig is a specialist endocrine surgeon and surgical oncologist from New South Wales, Australia. He is actively involved in the diagnosis and surgical management of a number of cancer types, but as a specialist endocrine surgeon his particular research interest is in prognostication and treatment of papillary thyroid cancer. Dr Craig has been working in collaboration with Oliver Bathe since 2018 when he travelled to Calgary to undertake further research and clinical training in endocrine surgery and surgical oncology.
Karen Hanna is a practicing lawyer and has been acting as our corporate legal counsel. Karen is a results-oriented lawyer that thrives on tackling new challenges and working as an integral part of a business team. She specializes in working with technology-based companies that require capitalization, have unique intellectual property portfolios, and are seeking best practices to assist them in achieving maximum value in contemplation of an exit event. Karen’s primary focus is on drafting and negotiating commercial contracts, helping disruptive technology become commercialized, navigating corporate finance requirements, ensuring transparency for stakeholders, and closing corporate acquisitions.
Dr. Adrian Harvey is an Associate Professor of Surgery & Oncology. He received his MD degree at the University of Toronto and holds master’s degrees in Human Biodynamics (McMaster University) and Medical Education (University of Toronto). He completed fellowship training in Endocrine Surgery at the Cleveland Clinic. His clinical practice includes a large volume of thyroid cancer patients. He has published on various topics related to endocrine surgery, including thyroid cancer.
Karen Kopciuk, PhD is an Associate Professor in the Department of Mathematics and Statistics, Community Health Sciences and Oncology at the University of Calgary. She is an expert in survival analysis, analysis of highly dimensional complex data sets, and estimating genetic risk. She has been collaborating with Oliver Bathe for over 20 years.
Brad Thomson is currently the CEO and Co-founder, Wyvern Pharmaceuticals Inc., and Kickshaw Ventures Ltd. He has been involved with biotechnology ventures for nearly 40 years, including 23 years as CEO of two NASDAQ listed biotech companies. He has founded and cofounded 18 biotech companies, of which nine went on to be publicly listed, and five were acquired by other companies. His areas of interest have been in autoimmune disease, oncology, and infectious diseases. His areas of expertise include, immunotherapy, oncology, infectious disease, autoimmune disease, corporate planning, strategic planning, M&A, and raising capital.
Don Wood was a caregiver for his late wife Sherry, who battled Stage 4 metastatic cancer for 3 years before losing her battle in early 2020. Don also lost his only brother Ken as a young adult who battled leukemia. Given these very personal experiences with the cancer journey, Don has dedicated his efforts to patient advocacy and engagement, and he is a philanthropist for cancer initiatives. He is currently, the Co-chair for the Strategic Cancer Network (SCN) Provincial Alberta Cancer Diagnosis (ACD) Design Team. He also serves on the Patient and Family Advisory Council (PFAC) for the Calgary Cancer Centre. Don is very active at national and provincial levels with 3CTN (Canadian Cancer Clinical Trials Network).